{"id":"calcipotriene-betamethasone-dipropionate","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation or burning at application site"},{"rate":null,"effect":"Hypercalcemia (with prolonged use or large surface area application)"},{"rate":null,"effect":"Skin atrophy (from corticosteroid component)"},{"rate":null,"effect":"Folliculitis"}]},"_chembl":null,"_dailymed":{"setId":"1d0ab2e6-1ab1-4d3e-ad55-7fa26446f191","title":"CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE SUSPENSION [SUN PHARMACEUTICAL INDUSTRIES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcipotriene binds to vitamin D receptors on keratinocytes and immune cells, promoting normal differentiation and reducing hyperproliferation characteristic of psoriasis. Betamethasone dipropionate acts as a glucocorticoid receptor agonist, suppressing inflammatory cytokines and immune cell infiltration. The combination provides synergistic anti-inflammatory and anti-proliferative effects on psoriatic plaques.","oneSentence":"Calcipotriene is a vitamin D analog that regulates skin cell differentiation and proliferation, while betamethasone dipropionate is a potent corticosteroid that reduces inflammation and immune response in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:34.913Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis (plaque psoriasis and other forms)"},{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT07357831","phase":"PHASE3","title":"A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-12-26","conditions":"Plaque Psoriasis","enrollment":537},{"nctId":"NCT05185258","phase":"PHASE4","title":"Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-02-16","conditions":"Psoriasis Vulgaris, Psoriasis, Skin Diseases","enrollment":12},{"nctId":"NCT05811234","phase":"","title":"A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2023-06-13","conditions":"Plaque Psoriasis","enrollment":291},{"nctId":"NCT06180473","phase":"","title":"Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-01-01","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT01195831","phase":"PHASE3","title":"Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-09","conditions":"Scalp Psoriasis","enrollment":244},{"nctId":"NCT00875277","phase":"PHASE2","title":"A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-04","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT01422434","phase":"PHASE3","title":"LEO 90105 Ointment in Japanese Subjects With Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-07","conditions":"Psoriasis","enrollment":676},{"nctId":"NCT00817219","phase":"PHASE2","title":"Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-07","conditions":"Psoriasis Vulgaris","enrollment":33},{"nctId":"NCT01768013","phase":"PHASE1, PHASE2","title":"The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-07","conditions":"Psoriasis Vulgaris","enrollment":13},{"nctId":"NCT01120223","phase":"PHASE2","title":"Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-05","conditions":"Scalp Psoriasis","enrollment":78},{"nctId":"NCT01083758","phase":"PHASE2","title":"Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-04","conditions":"Scalp Psoriasis","enrollment":31},{"nctId":"NCT02038569","phase":"PHASE2","title":"An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-01","conditions":"Psoriasis Vulgaris","enrollment":125},{"nctId":"NCT03806790","phase":"PHASE3","title":"Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2019-01-24","conditions":"Psoriasis Vulgaris","enrollment":182},{"nctId":"NCT01866163","phase":"PHASE3","title":"LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-06","conditions":"Psoriasis Vulgaris","enrollment":426},{"nctId":"NCT01188928","phase":"PHASE3","title":"LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-09","conditions":"Psoriasis Vulgaris","enrollment":1152},{"nctId":"NCT02132936","phase":"PHASE3","title":"LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-06","conditions":"Psoriasis Vulgaris","enrollment":504},{"nctId":"NCT02310646","phase":"PHASE3","title":"Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01","conditions":"Psoriasis Vulgaris","enrollment":219},{"nctId":"NCT00670241","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-04","conditions":"Psoriasis Vulgaris","enrollment":458},{"nctId":"NCT02668692","phase":"PHASE3","title":"LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-02","conditions":"Psoriasis Vulgaris","enrollment":213},{"nctId":"NCT02518048","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-08","conditions":"Skin and Connective Tissue Diseases","enrollment":35},{"nctId":"NCT01600222","phase":"PHASE2","title":"Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Psoriasis Vulgaris","enrollment":37},{"nctId":"NCT01536886","phase":"PHASE2","title":"LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Psoriasis Vulgaris","enrollment":376},{"nctId":"NCT01536938","phase":"PHASE2","title":"LEO 90100 in the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Psoriasis Vulgaris","enrollment":303},{"nctId":"NCT01347255","phase":"PHASE2","title":"A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-05","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT01837576","phase":"PHASE1","title":"An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-04","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT00216892","phase":"PHASE4","title":"Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-04","conditions":"Psoriasis Vulgaris","enrollment":1032},{"nctId":"NCT03898583","phase":"PHASE1","title":"Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2019-04-15","conditions":"Psoriasis Vulgaris","enrollment":15},{"nctId":"NCT00243464","phase":"PHASE3","title":"Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-09","conditions":"Psoriasis of Scalp","enrollment":300},{"nctId":"NCT02416258","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Skin and Connective Tissue Diseases","enrollment":50},{"nctId":"NCT00216827","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2004-11","conditions":"Psoriasis of Scalp","enrollment":1485},{"nctId":"NCT03442244","phase":"PHASE1","title":"Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-01-30","conditions":"Psoriasis Vulgaris","enrollment":20},{"nctId":"NCT00216879","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-02","conditions":"Psoriasis of Scalp","enrollment":800},{"nctId":"NCT01229098","phase":"PHASE2","title":"Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-10","conditions":"Psoriasis Vulgaris","enrollment":102},{"nctId":"NCT00248456","phase":"PHASE4","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-10","conditions":"Psoriasis Vulgaris","enrollment":320},{"nctId":"NCT00263718","phase":"PHASE2","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-12","conditions":"Psoriasis Vulgaris","enrollment":360},{"nctId":"NCT00279162","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-12","conditions":"Psoriasis","enrollment":160},{"nctId":"NCT00216840","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2004-12","conditions":"Psoriasis of Scalp","enrollment":1350},{"nctId":"NCT02379793","phase":"PHASE1","title":"Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-03","conditions":"Skin and Connective Tissue Diseases","enrollment":33},{"nctId":"NCT03476746","phase":"PHASE1","title":"Dermatopharmacokinetic Trial of LEO 90100 Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-03-20","conditions":"Healthy","enrollment":58},{"nctId":"NCT04227288","phase":"PHASE4","title":"A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-01","conditions":"Nail Psoriasis","enrollment":6},{"nctId":"NCT03308799","phase":"PHASE3","title":"A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2017-10-03","conditions":"Psoriasis Vulgaris","enrollment":794},{"nctId":"NCT03587194","phase":"PHASE4","title":"Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2018-07-23","conditions":"Psoriasis","enrollment":50},{"nctId":"NCT06329258","phase":"PHASE4","title":"Combination of Sotyktu and Enstilar for Plaque Psoriasis","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2022-12-06","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT06011083","phase":"NA","title":"Topical Calcipotriol /Betamethasone Ointment in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-08-01","conditions":"Psoriasis Vulgaris, Fractional CO2 Laser","enrollment":40},{"nctId":"NCT05249972","phase":"PHASE3","title":"A Phase III Study in Subjects With Mild to Moderate Psoriasis.","status":"UNKNOWN","sponsor":"Lipidor AB","startDate":"2022-01-24","conditions":"Mild to Moderate Psoriasis","enrollment":294},{"nctId":"NCT00437255","phase":"PHASE4","title":"Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-08","conditions":"Plaque Psoriasis","enrollment":122},{"nctId":"NCT04580537","phase":"PHASE2","title":"Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2020-10-02","conditions":"Nail Psoriasis","enrollment":11},{"nctId":"NCT00820950","phase":"PHASE2","title":"A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2007-05-31","conditions":"Psoriasis","enrollment":29},{"nctId":"NCT04380597","phase":"","title":"Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life","status":"COMPLETED","sponsor":"Angeles Florez","startDate":"2019-03-26","conditions":"Nail Psoriasis","enrollment":10},{"nctId":"NCT02935582","phase":"","title":"PSOREAL - Managing PSOriasis in the REAL World","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-01","conditions":"Psoriasis Vulgaris","enrollment":1214},{"nctId":"NCT03819218","phase":"PHASE2","title":"A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects","status":"TERMINATED","sponsor":"MC2 Therapeutics","startDate":"2018-12-27","conditions":"Psoriasis Vulgaris","enrollment":7},{"nctId":"NCT03506477","phase":"PHASE4","title":"Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-05-21","conditions":"Plaque Psoriasis, Psoriasis","enrollment":25},{"nctId":"NCT03802344","phase":"PHASE3","title":"This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-12-12","conditions":"Psoriasis Vulgaris","enrollment":498},{"nctId":"NCT04555707","phase":"PHASE4","title":"The Maintenance Effect of Enstilar Foam in Combination With Otezla","status":"UNKNOWN","sponsor":"Derm Research, PLLC","startDate":"2020-06-24","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT03848871","phase":"PHASE4","title":"The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2017-12-12","conditions":"Plaque Psoriasis","enrollment":20},{"nctId":"NCT03731091","phase":"PHASE3","title":"To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2018-10-31","conditions":"Psoriasis Vulgaris","enrollment":494},{"nctId":"NCT04372277","phase":"PHASE4","title":"Taltz in Combination With Enstilar for Psoriasis","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2020-04-28","conditions":"Psoriasis","enrollment":25},{"nctId":"NCT03899064","phase":"PHASE1","title":"Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2019-02-13","conditions":"Photoallergy","enrollment":58},{"nctId":"NCT03892564","phase":"PHASE1","title":"Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2019-02-27","conditions":"Phototoxicity","enrollment":35},{"nctId":"NCT03758365","phase":"PHASE1","title":"Evaluation of the Vasoconstriction Properties of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-11-05","conditions":"Vasoconstriction","enrollment":36},{"nctId":"NCT03462927","phase":"PHASE2","title":"A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-02-08","conditions":"Psoriasis Vulgaris","enrollment":63},{"nctId":"NCT02881346","phase":"","title":"Efficacy and Tolerability of Enstilar® in Daily Practice","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-09","conditions":"Plaque Psoriasis","enrollment":410},{"nctId":"NCT02636101","phase":"","title":"Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-01","conditions":"Psoriasis Vulgaris","enrollment":603},{"nctId":"NCT04071106","phase":"PHASE2, PHASE3","title":"Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2019-09-01","conditions":"Psoriasis","enrollment":50},{"nctId":"NCT02858713","phase":"PHASE4","title":"Adherence in Topical Treatment of Psoriasis","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2017-01-09","conditions":"Adherence","enrollment":134},{"nctId":"NCT03584360","phase":"PHASE2","title":"Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2018-09-24","conditions":"Psoriasis Vulgaris","enrollment":30},{"nctId":"NCT03880357","phase":"PHASE1","title":"To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2018-10-22","conditions":"Scalp Psoriasis","enrollment":485},{"nctId":"NCT03441789","phase":"PHASE4","title":"Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"L.H. Kircik, M.D.","startDate":"2017-09-18","conditions":"Plaque Psoriasis","enrollment":28},{"nctId":"NCT03004339","phase":"PHASE1","title":"Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test","status":"COMPLETED","sponsor":"DFB Soria, LLC","startDate":"2016-08","conditions":"Plaque Psoriasis","enrollment":13},{"nctId":"NCT03827876","phase":"PHASE4","title":"Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2019-01-16","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT03331523","phase":"PHASE3","title":"To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2017-10-20","conditions":"Scalp Psoriasis","enrollment":643},{"nctId":"NCT01707043","phase":"PHASE4","title":"Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2012-10","conditions":"Plaque Psoriasis","enrollment":20},{"nctId":"NCT03122353","phase":"PHASE1","title":"BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"Tolmar Inc.","startDate":"2017-04-11","conditions":"Scalp Psoriasis","enrollment":699},{"nctId":"NCT01982552","phase":"","title":"An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-07","conditions":"Psoriasis Vulgaris","enrollment":147},{"nctId":"NCT03399526","phase":"PHASE1","title":"1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-11","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT03080545","phase":"PHASE4","title":"Enstilar in Combination With Biologic Agents","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2017-05-01","conditions":"Psoriasis","enrollment":25},{"nctId":"NCT02856542","phase":"","title":"Real-life Evaluation of the Daivobet® Gel Applicator","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-05-23","conditions":"Plaque Psoriasis","enrollment":1560},{"nctId":"NCT02973776","phase":"PHASE1","title":"Vasoconstriction Trial With LEO 90100 Aerosol Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-12","conditions":"Psoriasis Vulgaris","enrollment":36},{"nctId":"NCT02940002","phase":"PHASE1","title":"BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-10-12","conditions":"Psoriasis","enrollment":23},{"nctId":"NCT01313221","phase":"PHASE3","title":"Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-04","conditions":"Psoriasis","enrollment":310},{"nctId":"NCT02999776","phase":"PHASE1","title":"Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis","status":"UNKNOWN","sponsor":"Pantec Biosolutions AG","startDate":"2016-11","conditions":"Psoriatic Plaque","enrollment":30},{"nctId":"NCT02955576","phase":"NA","title":"Microneedle Patch for Psoriatic Plaques","status":"UNKNOWN","sponsor":"The Catholic University of Korea","startDate":"2016-09","conditions":"Psoriasis, Administration, Topical","enrollment":20},{"nctId":"NCT00437619","phase":"PHASE4","title":"A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-02","conditions":"Psoriasis","enrollment":200},{"nctId":"NCT02489643","phase":"NA","title":"Individualized Medical Training and Calcipotriol and Betamethasone Dipropionate Gel in Plaque Psoriasis","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2014-05","conditions":"Psoriasis","enrollment":60},{"nctId":"NCT01233583","phase":"","title":"Regulatory T-cells in Psoriasis Patients as Targets for Therapy","status":"COMPLETED","sponsor":"University of Aberdeen","startDate":"2010-06","conditions":"Psoriasis","enrollment":38},{"nctId":"NCT02004574","phase":"PHASE4","title":"Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Jooheung Lee","startDate":"2013-10","conditions":"Psoriasis Vulgaris","enrollment":201},{"nctId":"NCT02114021","phase":"PHASE3","title":"Effect of Betamethasone Gel and Lidocaine Jelly on Sore Throat, Cough and Hoarseness of","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2012-03","conditions":"Sore Throat, Cough","enrollment":99},{"nctId":"NCT00608777","phase":"PHASE4","title":"Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)","status":"TERMINATED","sponsor":"Derm Research, PLLC","startDate":"2008-01","conditions":"Plaque Psoriasis","enrollment":6},{"nctId":"NCT01413477","phase":"NA","title":"Nickel Desensitization Using Topical Therapy","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2011-08","conditions":"Allergic Contact Dermatitis","enrollment":24},{"nctId":"NCT00574249","phase":"PHASE3","title":"Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-11","conditions":"Chronic Plaque Psoriasis","enrollment":730}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"PSORIASIS"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"PAIN IN EXTREMITY"},{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"APPENDICITIS"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ATRIAL FIBRILLATION"},{"count":1,"reaction":"BACK PAIN"},{"count":1,"reaction":"BREAST CANCER"}],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Enstilar"],"phase":"marketed","status":"active","brandName":"Calcipotriene + Betamethasone Dipropionate","genericName":"Calcipotriene + Betamethasone Dipropionate","companyName":"Odense University Hospital","companyId":"odense-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Calcipotriene is a vitamin D analog that regulates skin cell differentiation and proliferation, while betamethasone dipropionate is a potent corticosteroid that reduces inflammation and immune response in the skin. Used for Psoriasis (plaque psoriasis and other forms), Atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}